Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 375 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar optioncoach (98.53) Submitted: 1/23/2015 2:53:44 PM : Outperform Start Price: $105.43 GILD Score: +1.52

Biotech continues to lead the markets. GILD had a pretty tough hit with the pricing issue, but I feel that they have based out and will continue to prove to be a leader in their area of expertise. It is a new buy at this point.

Recs

0
Member Avatar pchop12316 (57.83) Submitted: 1/21/2015 1:33:46 PM : Outperform Start Price: $103.88 GILD Score: +1.65

still very undervalued

Recs

0
Member Avatar Jordrok (99.09) Submitted: 1/19/2015 7:54:34 PM : Outperform Start Price: $101.14 GILD Score: +4.40

Mechanical investing.

Recs

0
Member Avatar mike2r (< 20) Submitted: 1/19/2015 6:44:41 PM : Outperform Start Price: $101.14 GILD Score: +4.40

It has a very strong pipeline in areas that are very profitable. First, HIV. They have the only drug (Truvada) approved as a preventative measure and in their pipeline are working toward a one pill a day treatment for HIV.

In hepatitis, they have probably the strongest portfolio of drugs. Harvoni was recently released which cures Hepitits C in 8-12 weeks with one pill a day and no significant side effects.

For hepititis B they have two of the most effective treatments.

They also are developing a strong pipeline for cancer treatment.

Theses are all areas of significant opportunity and Despite the competitive environment, i think they are well positioned.

Recs

0
Member Avatar 1badbeerad (38.73) Submitted: 1/18/2015 1:19:25 AM : Outperform Start Price: $100.65 GILD Score: +4.13

Way undervalued.

Recs

0
Member Avatar Kidkerner (51.19) Submitted: 1/15/2015 9:02:11 AM : Outperform Start Price: $99.30 GILD Score: +5.97

Hep C, industry leader.

Recs

0
Member Avatar Popolago (< 20) Submitted: 1/8/2015 8:36:11 PM : Outperform Start Price: $103.52 GILD Score: +3.93

GREATLY UNDERVALUED

Recs

0
Member Avatar moneymn (74.87) Submitted: 1/7/2015 6:34:04 PM : Outperform Start Price: $100.80 GILD Score: +5.55

Superior pipeline and current drugs on the market

Recs

0
Member Avatar TMFHelical (99.14) Submitted: 1/7/2015 4:24:33 PM : Outperform Start Price: $96.67 GILD Score: +12.39

Good long term holding. The company has been creating value for some time. Added on an opportunistic drop created after Abbvie's competition in the Hep-C space got approval. Could dent Gilead in the short term, but not hardly in the long haul.

Recs

1
Member Avatar Kenji94 (58.76) Submitted: 1/2/2015 9:04:41 AM : Outperform Start Price: $95.14 GILD Score: +13.03

At least 20% below intrinsec value.

Recs

0
Member Avatar Kimer62 (29.88) Submitted: 12/27/2014 10:23:29 AM : Outperform Start Price: $93.71 GILD Score: +13.05

Strong company purchase on pull back from express scripts fiasco.

Recs

10
Member Avatar ABigelow (59.72) Submitted: 12/23/2014 11:38:08 AM : Outperform Start Price: $88.78 GILD Score: +21.86

Way, way, way oversold after the ABBV and ESRX deal was announced. GILD Hep C therapy is a better and easier drug to use. ABBV spent billions making an inferior drug that for some dumb a** reason makes you take 4-6 pills a day, one of which is a different Rx you have to buy. GILD is a one pill a day Rx. Thank you market for overselling and the future money you're about to make me.

Recs

0
Member Avatar Amoeba17 (62.88) Submitted: 12/22/2014 7:06:31 PM : Outperform Start Price: $93.41 GILD Score: +15.97

Took a hit on news that Express Scripts will be getting their Hep C drugs from elsewhere for a better price. I expect it to recover sooner than later.

Recs

0
Member Avatar TMFDeej (99.26) Submitted: 12/22/2014 4:03:36 PM : Outperform Start Price: $93.41 GILD Score: +15.97

Who doesn't like a good sale? I love to look at stocks that have been hammered by Mr. Market. Sometimes buying on big drops works, other times it doesn't. As long as it works more than half of the time, percentage-wise you're in good shape.

Many analysts think that the selloff in Gilead as a result of losing Express Scripts' Hep C business is overdone. This is a bet that it is.

Gilead Sciences: How Much Does AbbVie’s Express Scripts Deal Hurt?

http://blogs.barrons.com/stockstowatchtoday/2014/12/22/gilead-sciences-how-much-does-abbvies-express-scripts-deal-hurt/?mod=yahoobarrons&ru=yahoo

Jason

Recs

0
Member Avatar DAS313 (57.38) Submitted: 12/20/2014 10:06:46 AM : Outperform Start Price: $96.73 GILD Score: +11.36

Huge drug for almost endemic disease

Recs

0
Member Avatar Beginner110 (76.03) Submitted: 12/18/2014 5:53:34 PM : Outperform Start Price: $93.68 GILD Score: +15.00

A high risk situation with a reward to match the risk is successful. I believe the management shall succeed.

Recs

0
Member Avatar luremaster (36.41) Submitted: 12/18/2014 3:28:20 AM : Outperform Start Price: $104.47 GILD Score: +2.18

High quality, huge growth, low price

Recs

0
Member Avatar RW (68.09) Submitted: 12/15/2014 2:46:15 PM : Outperform Start Price: $102.95 GILD Score: +1.27

Gilead has a long track record for homeruns so I want to invest in their future. This seems like a good price too as the share price has been steadily dropping (which has caused me some short-term heart burn as I bought right before the drop.)

Recs

0
Member Avatar goLongWpicks (79.47) Submitted: 12/12/2014 3:49:11 PM : Outperform Start Price: $105.24 GILD Score: +0.06

Leader in HIV therapeutics and new Hep C drug is a blockbuster. Stock priced at 17x trailing non-GAAP eps. Looks cheap.

Recs

0
Member Avatar NuclearSteve (70.17) Submitted: 12/11/2014 10:48:13 AM : Outperform Start Price: $106.73 GILD Score: +0.55

Barron's article says stock is still cheap at roughly 10.5 times next years earnings while S&P trading at 17 times next years earnings.

Featured Broker Partners


Advertisement